GlassScriptPhysician profile
Rondai Evans
NPI 1295744357
$2,666.25
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $184 · 2021: $484 · 2022: $202 · 2023: $440 · 2024: $721 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $502.70 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $280.06 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Ivantis, INC | $270.55 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $250.78 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $197.54 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $187.76 | 2019-2023 | |
| Alcon Vision LLC | $156.36 | 2024-2025 | Eysuvis |
| Abbvie INC. | $142.07 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.47 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $121.53 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $119.57 | 2019-2021 | |
| Sight Sciences, INC. | $100.84 | 2022 | |
| Allergan, INC. | $90.07 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $44.67 | 2020-2021 | |
| Shire North American Group INC | $23.35 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $18.13 | 2021 | |
| Dompe US, INC. | $16.40 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rondai Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.